Based on the Aurinia Pharmaceuticals Inc stock forecast from 2 analysts, the average analyst target price for Aurinia Pharmaceuticals Inc is USD 11.50 over the next 12 months. Aurinia Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aurinia Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Aurinia Pharmaceuticals Inc’s stock price was USD 6.99. Aurinia Pharmaceuticals Inc’s stock price has changed by -2.65% over the past week, +0.14% over the past month and -3.45% over the last year.
No recent analyst target price found for Aurinia Pharmaceuticals Inc
No recent average analyst rating found for Aurinia Pharmaceuticals Inc
Company Overview Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Address: 118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6 Read Less
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephrit...Read More
Frequently Asked Questions About Aurinia Pharmaceuticals Inc (AUPH) Stock
Based on ratings from 2 analysts Aurinia Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on AUPH's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AUPH is USD 11.50 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on AUPH's stock to indicate if its overvalued.
The last closing price of AUPH's stock was USD 6.99.
The most recent market capitalization for AUPH is USD 1.01B.
Based on targets from 2 analysts, the average taret price for AUPH is projected at USD 11.50 over the next 12 months.
This means that AUPH's stock price may go up by +64.52% over the next 12 months.
We can't find any ETFs which contains Aurinia Pharmaceuticals Inc's stock.
As per our most recent records Aurinia Pharmaceuticals Inc has 300 Employees.
Aurinia Pharmaceuticals Inc's registered address is 118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6.
You can get more information about it from Aurinia Pharmaceuticals Inc's website at https://www.auriniapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Aurinia Pharmaceuticals Inc (AUPH) Stock
Based on ratings from 2 analysts Aurinia Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on AUPH's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AUPH is USD 11.50 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on AUPH's stock to indicate if its overvalued.
The last closing price of AUPH's stock was USD 6.99.
The most recent market capitalization for AUPH is USD 1.01B.
Based on targets from 2 analysts, the average taret price for AUPH is projected at USD 11.50 over the next 12 months.
This means that AUPH's stock price may go up by +64.52% over the next 12 months.
We can't find any ETFs which contains Aurinia Pharmaceuticals Inc's stock.
As per our most recent records Aurinia Pharmaceuticals Inc has 300 Employees.
Aurinia Pharmaceuticals Inc's registered address is 118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6.
You can get more information about it from Aurinia Pharmaceuticals Inc's website at https://www.auriniapharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AUPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
